Literature DB >> 18336053

Facilitation of drug evaluation in children by population methods and modelling.

Michel Tod1, Vincent Jullien, Gérard Pons.   

Abstract

The pharmacokinetics and pharmacodynamics of drugs are different in adult and paediatric populations, the latter being particularly heterogeneous. These differences in pharmacokinetics and pharmacodynamics justify specific studies but raise a number of ethical and practical issues. The main practical difficulties to circumvent while performing clinical studies in children are the invasiveness of the procedures and the obstacles to patient recruitment. The invasiveness related to pain/anxiety and blood loss precludes the performance of classical pharmacokinetic studies in children in many instances, particularly in neonates and infants. Population approaches, which rely on pharmacokinetic-pharmacodynamic modelling, are particularly appealing in paediatric populations because these models can cope with sparse data. The relevance of population approaches to investigation of the dose-concentration-effect relationships and to qualitative/quantitative assessment of factors that may explain interindividual variability has already been emphasized. The aims of this review are to summarize the currently available literature on population pharmacokinetic-pharmacodynamic studies in children and to discuss a number of recent methodological developments that may facilitate the evaluation of drugs in this population by alleviating invasiveness and, subsequently, facilitating recruitment of patients. The present survey confirms that population approaches in paediatrics have already reached a large audience and that they are mostly used for analysis of sparse data. However, pharmacokinetic-pharmacodynamic studies in children are still scarce. New classes of models may extend the scope of the use of population models in paediatrics. Kinetic-pharmacodynamic models, where use of the term 'kinetic' rather than 'pharmacokinetic' emphasizes the absence of pharmacokinetic data, are indirect models where the (unobserved) drug kinetics are described by a single compartment involving a single rate constant. These models, which alleviate the need for blood samples used for the measurement of drug concentration, may be very useful in paediatric studies. Physiological and physiopathological models also have potential applications but require further development. Because the number of measurements in a single individual needs to be limited in children, it is crucial to optimize the design of the experiment in order to avoid inaccurate and unreliable results. In this review, formal optimization and simulation to evaluate a design are presented, and specific problems raised by the application of these techniques in paediatrics are addressed. Finally, the related technique of clinical trial simulation and its applications are presented and discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18336053     DOI: 10.2165/00003088-200847040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  95 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

Review 3.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

5.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

6.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.

Authors:  Stephanie Läer; Jan-Peer Elshoff; Bernd Meibohm; Jochen Weil; Thomas S Mir; Wenhui Zhang; Martin Hulpke-Wette
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

8.  Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.

Authors:  Peter Lockwood; Wayne Ewy; David Hermann; Nick Holford
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

9.  Lack of pediatric drug formulations.

Authors:  M C Nahata
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  54 in total

1.  From adults to children: simulation-based choice of an appropriate sparse-sampling schedule.

Authors:  Stefanie Reif; Marcus Schultze-Mosgau; Gabriele Sutter
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

2.  Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Authors:  Sophie Peigné; François Bouzom; Karl Brendel; Charlotte Gesson; Sylvain Fouliard; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-12       Impact factor: 2.745

3.  Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.

Authors:  Amélie Marsot; F Gallais; C Galambrun; C Coze; O Blin; N Andre; R Guilhaumou
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

4.  First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

Authors:  Ashley Strougo; Thomas Eissing; Ashraf Yassen; Stefan Willmann; Meindert Danhof; Jan Freijer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-02-05       Impact factor: 2.745

5.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

6.  Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.

Authors:  Efthymios Manolis; Gérard Pons
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 7.  How to optimize the evaluation and use of antibiotics in neonates.

Authors:  Evelyne Jacqz-Aigrain; Florentia Kaguelidou; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-09-01       Impact factor: 3.278

8.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.

Authors:  Sophie Peigné; Sylvain Fouliard; Sophie Decourcelle; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-14       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.